These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 1489207)
1. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Jakics EB; Iyobe S; Hirai K; Fukuda H; Hashimoto H Antimicrob Agents Chemother; 1992 Nov; 36(11):2562-5. PubMed ID: 1489207 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Poole K; Gotoh N; Tsujimoto H; Zhao Q; Wada A; Yamasaki T; Neshat S; Yamagishi J; Li XZ; Nishino T Mol Microbiol; 1996 Aug; 21(4):713-24. PubMed ID: 8878035 [TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of a DNA fragment that complements the nfxB mutation in Pseudomonas aeruginosa PAO. Okazaki T; Iyobe S; Hashimoto H; Hirai K FEMS Microbiol Lett; 1991 Mar; 63(1):31-5. PubMed ID: 1904383 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Yoshida T; Muratani T; Iyobe S; Mitsuhashi S Antimicrob Agents Chemother; 1994 Jul; 38(7):1466-9. PubMed ID: 7979273 [TBL] [Abstract][Full Text] [Related]
6. Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Hosaka M; Gotoh N; Nishino T Antimicrob Agents Chemother; 1995 Aug; 39(8):1731-5. PubMed ID: 7486910 [TBL] [Abstract][Full Text] [Related]
7. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Fukuda H; Hosaka M; Hirai K; Iyobe S Antimicrob Agents Chemother; 1990 Sep; 34(9):1757-61. PubMed ID: 2126688 [TBL] [Abstract][Full Text] [Related]
8. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Li XZ; Livermore DM; Nikaido H Antimicrob Agents Chemother; 1994 Aug; 38(8):1732-41. PubMed ID: 7986003 [TBL] [Abstract][Full Text] [Related]
9. [Development of multi-drug resistant mutants of clinical isolates of Pseudomonas aeruginosa after exposure to fluoroquinolone]. Hasegawa M; Kobayashi I; Saika T; Shimadzu M; Nishida M Kansenshogaku Zasshi; 1996 Feb; 70(2):123-31. PubMed ID: 8851384 [TBL] [Abstract][Full Text] [Related]
10. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. Livermore DM; Yang YJ J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657 [TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial activities of norfloxacin against clinical isolates from ocular infections]. Koguchi M; Suzuki Y; Tanaka S; Fukayama S; Ishihara R; Deguchi K; Oda S; Nakane Y; Fukumoto T Jpn J Antibiot; 1995 Aug; 48(8):1009-25. PubMed ID: 7474324 [TBL] [Abstract][Full Text] [Related]
12. In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics. Wretland B; Nord CE; Wadström T Scand J Infect Dis; 1974; 6(1):49-52. PubMed ID: 4208204 [No Abstract] [Full Text] [Related]
13. Transferable imipenem resistance in Pseudomonas aeruginosa. Watanabe M; Iyobe S; Inoue M; Mitsuhashi S Antimicrob Agents Chemother; 1991 Jan; 35(1):147-51. PubMed ID: 1901695 [TBL] [Abstract][Full Text] [Related]
14. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. Aubert G; Pozzetto B; Dorche G J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371 [TBL] [Abstract][Full Text] [Related]
15. Studies on the susceptibility of 150 consecutive clinical isolates of Pseudomonas aeruginosa to tobramycin, gentamicin, colistin, carbenicillin, and five other antimicrobials. Lockwood WR; Lawson LA Antimicrob Agents Chemother; 1973 Sep; 4(3):281-4. PubMed ID: 4202342 [TBL] [Abstract][Full Text] [Related]
16. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Young ML; Bains M; Bell A; Hancock RE Antimicrob Agents Chemother; 1992 Nov; 36(11):2566-8. PubMed ID: 1336952 [TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of ciprofloxacin and other beta-lactam antibiotics against gentamicin- and carbenicillin-resistant isolates of Pseudomonas aeruginosa. Sofianou DC; Douboyas JP J Chemother; 1991 Feb; 3(1):3-5. PubMed ID: 1902252 [TBL] [Abstract][Full Text] [Related]
18. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. Ogle JW; Reller LB; Vasil ML J Infect Dis; 1988 Apr; 157(4):743-8. PubMed ID: 3126247 [TBL] [Abstract][Full Text] [Related]
19. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Masuda N; Gotoh N; Ohya S; Nishino T Antimicrob Agents Chemother; 1996 Apr; 40(4):909-13. PubMed ID: 8849250 [TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. Chen HY; Livermore DM J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]